Long-term results of combination treatment with single-dose ranibizumab plus photodynamic therapy for retinal angiomatous proliferation
Ophthalmologica May 19, 2018
Malamos P, et al. - Authors sought to assess functional and anatomic outcomes of combination therapy with ranibizumab and photodynamic therapy (PDT) in a series of retinal angiomatous proliferation (RAP) cases. Findings demonstrated that at the initial stages of RAP, long-term regression could be provided with single-dose modified anti-VEGF treatment in combination with PDT. A correlation of the rate of hotspot occlusion with the stage of disease was seen. In posttreatment BCVA, there was a significant improvement for all patients regardless of disease stage, which was more evident in the earlier stages. Greater improvement was seen in treatment-naive patients. Experts noted a close association of the posttreatment improvement in BCVA with hotspot occlusion.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries